Rockefeller Capital Management L.P. Cuts Stock Position in Jazz Pharmaceuticals PLC $JAZZ

Rockefeller Capital Management L.P. cut its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 4.3% in the fourth quarter, HoldingsChannel.com reports. The fund owned 265,056 shares of the specialty pharmaceutical company’s stock after selling 11,816 shares during the period. Rockefeller Capital Management L.P.’s holdings in Jazz Pharmaceuticals were worth $45,060,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Hilltop National Bank acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $36,000. LRI Investments LLC acquired a new stake in Jazz Pharmaceuticals in the 4th quarter worth about $38,000. Leonteq Securities AG acquired a new stake in Jazz Pharmaceuticals in the 4th quarter worth about $50,000. GoalVest Advisory LLC purchased a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $51,000. Finally, Danske Bank A S purchased a new stake in Jazz Pharmaceuticals during the 3rd quarter worth approximately $40,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on JAZZ shares. Sanford C. Bernstein restated a “market perform” rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, June 9th. Barclays boosted their price target on Jazz Pharmaceuticals from $234.00 to $253.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 27th. Robert W. Baird set a $252.00 price objective on Jazz Pharmaceuticals in a report on Wednesday, May 6th. TD Cowen lifted their target price on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, Wells Fargo & Company lifted their target price on shares of Jazz Pharmaceuticals from $250.00 to $265.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Sixteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $246.06.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $224.66 on Friday. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. The company’s 50 day simple moving average is $221.33 and its two-hundred day simple moving average is $190.53. Jazz Pharmaceuticals PLC has a 1-year low of $105.00 and a 1-year high of $243.32. The firm has a market capitalization of $14.11 billion, a price-to-earnings ratio of -11,227.39, a price-to-earnings-growth ratio of 0.20 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The business had revenue of $1.07 billion during the quarter. Analysts expect that Jazz Pharmaceuticals PLC will post 22.09 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total transaction of $1,143,000.00. Following the completion of the sale, the director directly owned 384,682 shares in the company, valued at approximately $73,281,921. This trade represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total transaction of $278,196.00. Following the completion of the transaction, the executive vice president owned 51,549 shares in the company, valued at $11,950,604.67. The trade was a 2.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 13,098 shares of company stock worth $2,832,086 over the last quarter. Corporate insiders own 4.10% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.